Pilot Study of FLT3 Ligand Prior to Resection of Hepatic Metastases of Colorectal Cancer
OBJECTIVES: I. Evaluate the safety and feasibility of administering flt3 ligand to patients
with hepatic metastases from colorectal cancer prior to surgical resection.
OUTLINE: Patients receive flt3 ligand subcutaneously for 14 days followed by 14 days of
rest. This course of therapy may be repeated for a total of 3 courses. Leukapheresis is
performed on day 15 of the last course of Flt3 ligand. Patients undergo restaging and
metastasis resection. Patients are followed every 3 months for the first year, every 6
months for the second year, and yearly thereafter.
PROJECTED ACCRUAL: This study will accrue 12 patients in 1 year.
Primary Purpose: Treatment
Michael A. Morse, MD
Duke Cancer Institute
United States: Federal Government
|Duke Comprehensive Cancer Center||Durham, North Carolina 27710|